Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway

Leng, Jing; Huang, Fu; Hai, Yamei; Tian, Huayu; Liu, Wei; Fang, Yi; Hu, Yiyang; Peng, Jinghua

doi:10.1016/j.phymed.2019.153135

Cited by 31 publications

(31 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent decades, herbal therapy has been validated as an effective therapeutic strategy for the treatment of NAFLD and its related disorders [22,[111][112][113]. The concurrence and development of NAFLD had closed relationship with the imbalance of intestinal microecology.…”

Section: Discussionmentioning

confidence: 99%

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology

et al. 2021

View full text Add to dashboard Cite

The worldwide prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, and this metabolic disorder has been recognized as a severe threat to human health. A variety of chemical drugs have been approved for treating NAFLD, however, they always has serious side effects. Chinese herbal medicines (CHMs) have been widely used for preventing and treating a range of metabolic diseases with satisfactory safety and effective performance in clinical treatment of NAFLD. Recent studies indicated that imbanlance of the intestinal microbiota was closely associated with the occurrence and development of NAFLD, thus, the intestinal microbiota has been recognized as a promising target for treatment of NAFLD. In recent decades, a variety of CHMs have been reported to effectively prevent or treat NAFLD by modulating intestinal microbiota to further interfer the gut-liver axis. In this review, recent advances in CHMs for the treatment of NAFLD via rebuilding the intestinal microecology were systematically reviewed. The key roles of CHMs in the regulation of gut microbiota and the gut-liver axis along with their mechanisms (such as modulating intestinal permeability, reducing the inflammatory response, protecting liver cells, improving lipid metabolism, and modulating nuclear receptors), were well summarized. All the knowledge and information presented here will be very helpful for researchers to better understand the applications and mechanisms of CHMs for treatment of NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In rats with liver cirrhosis induced by carbon tetrachloride (CCl 4 ), Artesunate (an extract of Artemisia annua ) has been shown to increase levels of Lactobacillus and Eubacterium , thereby reducing the concentration of proinflammatory IL-6 and TNF- α , reducing injury to the intestinal mucosa, and decreasing the numbers of translocated bacteria [ 77 ]. TCM compounds, such as Qushi Huayu decoction and Erzhi pills, are also capable of modifying the composition of the intestinal flora, which can affect fatty liver disease [ 73 , 87 ].…”

Section: Intervention Therapy Using Traditional Chinese Medicine (Tcm)mentioning

confidence: 99%

Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine

Wang

Huang²,

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Liver disease is a leading cause of global morbidity and mortality, for which inflammation, alcohol use, lipid metabolic disorders, disturbance to bile acid metabolism, and endotoxins are common risk factors. Traditional Chinese Medicine (TCM) with its “holistic approach” is widely used throughout the world as a complementary, alternative therapy, due to its clinical efficacy and reduced side effects compared with conventional medicines. However, due to a lack of reliable scientific evidence, the role of TCM in the prevention and treatment of liver disease remains unclear. Over recent years, with the rapid development of high-throughput sequencing, 16S rRNA detection, and bioinformatics methodology, it has been gradually recognized that the regulation of intestinal microbiota by TCM can play a substantial role in the treatment of liver disease. To better understand how TCM regulates the intestinal microbiota and suppresses liver disease, we have reviewed and analyzed the results of existing studies and summarized the relationship and risk factors between intestinal microbiota and liver disease. The present review summarizes the related mechanisms by which TCM affects the composition and metabolites of the intestinal microbiome.

show abstract

“…There were many other examples highlighting the microbial change during the treatment of obesity, diabetes and metabolic syndromes (Table 1). These examples include Daesiho-Tang (DSHT) that attenuated obesity and significantly increased the relative abundance of Bacteroidetes, B/F ratio, Akkermansia, Bifidobacterium, Lactobacillus, and decreased the level of Firmicutes (Hussain et al, 2016), Gegen Qinlian Decoction (GQD) alleviated Type 2 diabetes and significantly increased Faecalibacterium prausnitzii (Xu et al, 2015), while Qushi Huayu Decoction (QHD) reduced HFD-induced non-alcoholic fatty liver disease (NAFLD), and significantly increased the abundance of Parabacteroides and decreased the abundance of Odoribacter, Rikenella, Tyzzerella, Intestinibacter, Romboutsia and 2 members in Lachnospiraceae (Leng et al, 2020). Other examples related to gut microbiota changes included (Table 1): 20% Folium Mori amelioration of diabetes (Zhang et al, 2019a), Xiexin Tang-mediated improvement of type 2 diabetes (Wei et al, 2018), amelioration of human type 2 diabetes by metformin and a traditional Chinese herbal formula, AMC (Tong et al, 2018), Huang-Lian-Jie-Du decoction-mediated treatment of hyperglycemia and insulin resistance (Chen et al, 2018b), improvement of type 2 diabetes by treatment with Qijian (Gao et al, 2018), Banxia Xiexin decoction on diabetic gastroparesis rats (Xu et al, 2018), Houttuynia cordata facilitation of metformin on reducing insulin resistance (Wang et al, 2017b), berberine, the main bioactive alkaloid of Coptis chinensis, on glucolipid metabolism and insulin resistance in diabetic mice (Han et al, 2016;Liu et al, 2018a), and rhein's role in antidiabetic effects (Wang et al, 2018b).…”

Section: Close Interaction Between Tcm Herbs and Gut Microbiota In DImentioning

confidence: 99%

Role of gut microbiota in identification of novel TCM-derived active metabolites

Lin

Lai

et al. 2020

Protein Cell

View full text Add to dashboard Cite

Traditional Chinese Medicine (TCM) has been extensively used to ameliorate diseases in Asia for over thousands of years. However, owing to a lack of formal scientific validation, the absence of information regarding the mechanisms underlying TCMs restricts their application. After oral administration, TCM herbal ingredients frequently are not directly absorbed by the host, but rather enter the intestine to be transformed by gut microbiota. The gut microbiota is a microbial community living in animal intestines, and functions to maintain host homeostasis and health. Increasing evidences indicate that TCM herbs closely affect gut microbiota composition, which is associated with the conversion of herbal components into active metabolites. These may significantly affect the therapeutic activity of TCMs. Microbiota analyses, in conjunction with modern multiomics platforms, can together identify novel functional metabolites and form the basis of future TCM research.

show abstract

Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway

Cited by 31 publications

References 62 publications

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology

Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine

Role of gut microbiota in identification of novel TCM-derived active metabolites

Contact Info

Product

Resources

About